PI3k/AKT/mTOR inhibitor (Sonitu)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug NamePI3k/AKT/mTOR inhibitor (Sonitu)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerine/threonine-protein kinase mTOR inhibitorsPI3-kinase class I inhibitorsProto-oncogene proteins c-akt inhibitors
TargetsPI3-kinase class IProto-oncogene proteins c-aktSerine/threonine-protein kinase mTOR
Therapy Area/IndicationsCarcinoma, Hepatocellular
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesSONITU Pharmaceuticals LLC
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSONITU Pharmaceuticals LLC
Active IndicationsN/A
Inactive IndicationsCarcinoma, Hepatocellular

Other Information

ATC CodeN/A
Related LinksN/A